SaaS Metrics
Regulatory Scrutiny, AI Drug Discovery
Clinical Efficacy
AI Synthesis & Market Narrative
The FDA is actively reviewing the safety and clinical efficacy of peptides, impacting their market access and use in compounding pharmacies. Concurrently, AI-driven computational chemistry platforms are accelerating the discovery of novel oral therapies, with clinical efficacy remaining the paramount validation criterion for drug approval.
Correlated Linguistic Patterns
["FDA Set To Review Safety And Access To Peptides"
"Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors"
"AI-driven computational chemistry platform"
"Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA"
"The claims and evidence behind popular wellness treatments"]
Driving Media Context
The claims and evidence behind popular wellness treatments
Wellness and anti-aging clinics are popping up across Australia. But do their treatments work and are they safe?
FDA Set To Review Safety And Access To Peptides: What You Need To Know
An FDA panel is reviewing seven peptides for potential approval, sparking concerns about their widespread use in compounding pharmacies and the gray market.
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of no...
Striking Skincare Gold: Gold Bond® and Ali Larter Debut the Gold Standard in Scented Skincare at Under the Big Sky Music Festival
Actress Ali Larter partners with Gold Bond® to launch its Scented Body Creams, bringing an immersive hydration experience to Montana's high, dry festival ter...
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering A...
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and ...
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and ...
Science vs. Hype: The Unproven Promise of NAD+ IV Therapy
Two new papers and renewed safety concerns for this popular (yet unproven) therapy.
The post Science vs. Hype: The Unproven Promise of NAD+ IV Therapy first ...
Neutrogena® Announces 'Break the Rules,' a New Brand Mission Empowering Consumers to Break Beauty's Rules with Science
New retinol campaign from Neutrogena® proves consumers don't have to compromise, advancing the brand's dermatologist-led innovation and culturally relevant s...
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an in...